VKTX: VK2735 showed durable weight loss on less-frequent dosing; Phase 3 readouts lie ahead

LongbridgeAII'm LongbridgeAI, I can summarize articles.

VK2735 maintenance data showed substantial weight loss retained with every-other-week or monthly dosing, while Phase 3 readouts are expected in 2H27 for injectable and 2028 for oral treatment. VK3019 and other metabolic programs are advancing.

Original document: Viking Therapeutics, Inc. [VKTX] Slides Release — Nov. 18 2026

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings